Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics, Inc. develops genetic medicines and other neurotherapeutics for neurological diseases, with company updates focused on its CNS pipeline and delivery platforms. Recurring news covers the TRACER AAV capsid discovery platform, intravenous gene-therapy research, Voyager NeuroShuttle nonviral delivery work, and programs addressing Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, ALS, frontotemporal dementia and other central nervous system disorders.
Company announcements also cover tau-focused assets such as VY1706 and VY7523, small-molecule discovery collaboration targeting TDP-43 pathology, scientific conference presentations, and periodic financial and operating results. Voyager’s updates frequently connect pipeline spending, collaboration revenue, partner programs and balance-sheet resources with its genetic-medicine development strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Voyager Therapeutics (Nasdaq: VYGR) recently presented new data at the AD/PD Conference in Gothenburg, Sweden, focusing on its anti-tau antibody program for Alzheimer's disease and GBA1 gene therapy for Parkinson's disease. The anti-tau antibody, VY-TAU01, has been selected as the lead candidate with an IND filing expected in H1 2024. In partnership with Neurocrine Biosciences, the GBA1 gene therapy program showed promising results in mouse models, demonstrating significant improvements in efficacy biomarkers. This data reinforces Voyager's commitment to advancing innovative gene therapy approaches in neurology.